BWAY - Brainsway Ltd.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
12.11
-0.20 (-1.62%)
As of 9:30AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close12.31
Open12.42
Bid12.14 x 1200
Ask12.32 x 900
Day's Range12.11 - 12.11
52 Week Range8.00 - 12.53
Volume30
Avg. Volume11,556
Market Cap136.828M
Beta (5Y Monthly)0.56
PE Ratio (TTM)N/A
EPS (TTM)-1.09
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est16.44
  • GlobeNewswire

    Greenbrook TMS NeuroHealth Centers Now Offer BrainsWay’s Deep Transcranial Magnetic Stimulation (Deep TMS) for Obsessive-Compulsive Disorder (OCD) in Cary, North Carolina

    Greenbrook TMS NeuroHealth Centers, one of the leading providers of Transcranial Magnetic Stimulation (TMS) therapy in the United States, announced today that it is now offering BrainsWay’s Deep TMS therapy for patients with obsessive-compulsive disorder (OCD) at its Greenbrook - Cary facility in North Carolina. “We are eager to offer BrainsWay’s Deep TMS helmet as an option for patients with OCD in Raleigh and Durham, especially for those who find themselves resistant to traditional forms of treatment,” said Dr. Kellie Tolin, regional medical director of North Carolina for Greenbrook TMS.

  • GlobeNewswire

    Greenbrook TMS NeuroHealth Center in Newport News Now Offering BrainsWay’s Deep Transcranial Magnetic Stimulation (Deep TMS) for Obsessive-Compulsive Disorder (OCD)

    Greenbrook TMS NeuroHealth Centers, one of the leading providers of mental health services in the United States, is now offering BrainsWay’s Deep Transcranial Magnetic Stimulation (Deep TMS) therapy for patients with obsessive-compulsive disorder (OCD) at their Newport News location in Virginia. “We’re proud to announce that Greenbrook TMS is now offering BrainsWay’s Deep TMS device for OCD across our offices in Virginia, with the latest being Newport News,” said Dr. William Sauve, regional medical director of Virginia for Greenbrook TMS.

  • MarketWatch

    Brainsway shares up on smoking cessation data

    Shares of Brainsway are up 10% in premarket trading on positive trial results for its brain stimulation device as a smoking cessation tool for longtime chronic cigarette smokers. About 20% of the patients in the study who completed treatment reported a four-week continuous quit rate, compared to 8% in the placebo group. "The success demonstrated in this study in treating patients addicted to cigarettes strengthens our optimism with respect to the potential for the use of our platform technology to treat other addictions as well," Brainsway interim CEO David Zacut said in a news release. The Israeli medical device maker went public in April. Its stock has fallen 8% over the last three months, while the S&P 500 has gone up 7% during the same period.

  • GlobeNewswire

    BrainsWay Announces Successful Results in Pivotal Multicenter Study Evaluating Deep Transcranial Magnetic Stimulation System as an Aid in Smoking Cessation

    BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay”) today announced final positive results from its pivotal multicenter trial assessing the safety and efficacy of the Company’s H4 Deep transcranial magnetic stimulation system (Deep TMS) as an aid in smoking cessation in adults suffering from chronic smoking addiction. This trial represents the first multicenter pivotal study conducted with any non-invasive brain stimulation device in the addiction space.

  • GlobeNewswire

    BrainsWay Reports Third Quarter 2019 Financial Results and Operational Highlights

    JERUSALEM, Israel and HACKENSACK, N.J., Nov. 25, 2019 -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive.

  • GlobeNewswire

    BrainsWay Appoints Medical Technology Industry Leader Christopher R. von Jako, Ph.D., as President and Chief Executive Officer

    BrainsWay Ltd. (NASDAQ & TASE: BWAY) and its subsidiary BrainsWay USA, Inc., a global leader in the advanced non-invasive treatment of brain disorders, today announced that its Board of Directors has decided to appoint Christopher von Jako, Ph.D., as President and Chief Executive Officer (CEO). Dr. von Jako’s appointment cements the Board's commitment to a strategic transition to U.S.-based leadership, and will become effective in January 2020. “Dr. von Jako is a science-driven senior executive with over 25 years of experience managing businesses and leading global medical technology companies,” said Dr. David Zacut, a co-founder of BrainsWay and Chairman of the Board, who has been serving as Interim CEO since September 2019.

  • GlobeNewswire

    BrainsWay‘s New Stimulator for Deep Transcranial Magnetic Stimulation Makes German Debut at the 2019 German Association for Psychiatry, Psychotherapy and Psychosomatics Congress

    BrainsWay Ltd. (NASDAQ: BWAY, TASE: BWAY), a global leader in the advanced non-invasive treatment of brain disorders, announced today that it will be exhibiting its new state-of-the-art deep transcranial magnetic stimulation (dTMS) platform for the first time in Germany, at the 2019 German Association for Psychiatry, Psychotherapy and Psychosomatics (DGPPN) Congress scheduled to take place in Berlin from November 27-30, 2019. The platform includes the company’s new proprietary stimulator and is designed to treat a variety of neuropsychiatric conditions, including Major Depressive Disorder (MDD) and Obsessive-Compulsive Disorder (OCD). BrainsWay will be conducting individual, hands-on demonstrations for interested healthcare professionals at booth #12, providing them with an up-close and personal experience with the new dTMS stimulator and a better understanding of its operation and practice implementation.

  • GlobeNewswire

    BrainsWay to Report Third Quarter 2019 Financial Results on November 25, 2019

    BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of brain disorders, today announced that it will report its third quarter 2019 financial results before the opening of the U.S. financial markets on Monday, November 25, 2019. The company will host a conference call at 9:00 AM Eastern Time to review the financial results and operational highlights. The conference call will be broadcast live and will be available for replay for 30 days on the Company's website, https://investors.brainsway.com/financial-calendar .Please access the Company's website at least 15 minutes ahead of the conference call to register.

  • GlobeNewswire

    TMS Program Hosts Open House to Introduce Deep Transcranial Magnetic Stimulation (Deep TMS) Helmet to Treat Major Depressive Disorder (MDD) and Obsessive-Compulsive Disorder (OCD)

    TMS Program, a mental health clinic that provides treatments to a wide range of psychiatric disorders, today announced that it will host an open house on Thursday, Nov. 14 from 4:00 p.m. until 7:00 p.m. The event will feature a chance for attendees to meet the staff at the clinic and will introduce one of the most effective offerings, BrainsWay’s Deep Transcranial Magnetic Stimulation (Deep TMS) for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). “At TMS Program, fwe strive to provide quality care and act as an effective source for our patients during treatment,” said Dr. Al Dalkilic, M.D., M.P.H., and medical director at TMS Program.

  • GlobeNewswire

    A Stepping Stone Hosts Open House to Introduce Newly Offered FDA-Cleared Helmet to Treat Major Depressive Disorder (MDD)

    A Stepping Stone, a full-service outpatient mental health clinic with advanced treatments for mental health disorders, announced today that it will host an open house on Nov. 12. The event will feature a chance for the public to meet the staff at the clinic and will introduce the latest offering, BrainsWay’s Deep Transcranial Magnetic Stimulation (Deep TMS) for the treatment of major depressive disorder (MDD). “Our highly diverse staff prioritizes the well-being of our patients, which is why we are excited to expand our treatment options for those living with depression,” said Dr. Arshad William, M.D., a psychiatrist at A Stepping Stone.

  • GlobeNewswire

    Family Wellness Center of Norman Hosts Open House to Introduce Newly Offered FDA-Cleared Deep TMS Helmet to Treat Major Depressive Disorder (MDD)

    Family Wellness Center of Norman, a full-service mental health clinic with advanced treatments for mental health disorders, announced today that it will host an open house on Wednesday, Oct. 23 from 4:00 p.m. - 6:00 p.m. The event will feature a demonstration of BrainsWay’s Deep Transcranial Magnetic Stimulation (Deep TMS) for the treatment of major depressive disorder (MDD) and will offer the public a chance to meet the staff at the clinic. “Patients with MDD often find themselves resistant to traditional treatments such as medication or therapy,” said Susan Thompson APRN-CNP, psychiatric nurse practitioner and owner at Family Wellness Center of Norman.

  • GlobeNewswire

    BrainsWay Announces Innovative Deep Transcranial Magnetic Stimulation System Showcase Presentation at this Year’s Psych Congress Meeting

    BrainsWay Ltd. (NASDAQ: BWAY, TASE: BWAY), a global leader in the advanced non-invasive treatment of brain disorders, announced today they will be hosting “Advances in Neuromodulation for the Treatment of Neuropsychiatric Conditions”, an innovation showcase on their deep transcranial magnetic stimulation (dTMS) device, as well as other educational activities, during the Psych Congress Meeting being held from October 3-6 in San Diego, CA. Manish Sheth, MD, Ph.D., from Achieve TMS will be presenting at the innovation showcase and will discuss key advances in neuromodulation, such as dTMS, to treat a number of neuropsychiatric conditions, including Major Depressive Disorder (MDD) as well as Obsessive Compulsive Disorder (OCD).

  • GlobeNewswire

    Achieve TMS East Celebrates the Opening of a New Office in West Hartford, Connecticut

    WEST HARTFORD, Conn., Sept. 24, 2019 -- Achieve TMS East,​ New England’s largest provider of Deep Transcranial Magnetic Stimulation (Deep TMS) therapy for the treatment of.

  • GlobeNewswire

    BrainsWay Announces Further Leadership Transition to U.S.

    JERUSALEM and HACKENSACK, N.J., Sept. 19, 2019 -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced, non-invasive.

  • GlobeNewswire

    Square Medical Group is Now Offering Mental Health Technology for Major Depressive Disorder (MDD) in Offices Across Massachusetts

    Square Medical Group, an integrated, multidisciplinary private group practice providing a full-range of outpatient mental health and chemical dependency services, is now offering BrainsWay’s Deep Transcranial Magnetic Stimulation (Deep TMS) therapy for Major Depressive Disorder (MDD) at their locations in Watertown, Concord, Weymouth, and most recently, Danvers. “Square Medical Group’s unique value is our ability to provide the region’s most extensive continuum of care for our patients,” said Dr. Natalie L. Lender, MD, chief medical officer at Square Medical Group.

  • GlobeNewswire

    Catalyst Psychiatry Now Offering Mental Health Technology for Patients with Major Depressive Disorder (MDD) and Obsessive-Compulsive Disorder (OCD) in Corvallis

    Catalyst Psychiatry, a provider of mental health services in Oregon, is now offering BrainsWay’s Deep Transcranial Magnetic Stimulation (Deep TMS) therapy for patients with Major Depressive Disorder (MDD) and Obsessive-Compulsive Disorder (OCD). Catalyst Psychiatry has been operating in Corvallis since 2014, and has since established itself as one of the premier mental health providers in the area by offering the latest technologies to the community.

  • GlobeNewswire

    Brainsway Reports Second Quarter 2019 Financial Results and Operational Highlights

    JERUSALEM, Israel and HACKENSACK, N.J., Aug. 26, 2019 -- Brainsway Ltd. (NASDAQ & TASE: BWAY) (“Brainsway” or the “Company”), a global leader in the advanced non-invasive.

  • ACCESSWIRE

    Brainsway Ltd. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 26, 2019 / Brainsway Ltd. (NASDAQ: BWAY ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on August 26, 2019 at 8:00 AM Eastern ...

  • GlobeNewswire

    BrainsWay Ltd. to Host Second Quarter 2019 Financial Results Conference Call on August 26, 2019

    BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of brain disorders, today announced that it will report its second quarter 2019 financial results and operational highlights on Monday, August 26, 2019. The Company will host a conference call on Monday, August 26, 2019 at 8:00 a.m. Eastern Time to review the financial results and operational highlights. The conference call will be broadcast live and will be available for replay for 30 days on the Company's website, https://investors.brainsway.com/financial-calendar.

  • GlobeNewswire

    New York Psychiatrist, Dr. Aleksandra Krunic, Introduces Groundbreaking FDA-Cleared Helmet to Treat Obsessive-Compulsive Disorder (OCD)

    Dr. Aleksandra Krunic, head of Child and Adult Clinical Psychiatry New York, a top psychiatric clinic serving patients in Long Island and New York City with a variety of advanced treatments for mental health disorders, announced today that the company will be introducing BrainsWay's Deep Transcranial Magnetic Stimulation (Deep TMS) for the treatment of Obsessive-Compulsive Disorder (OCD).

  • GlobeNewswire

    Achieve TMS East Celebrates the Opening of its Haverhill Location July 25, 2019

    Achieve TMS East, Massachusetts’ largest provider of deep TMS therapy for the treatment of Depression and OCD, is pleased to announce the opening of its newest center in Haverhill, MA. Achieve TMS East will be celebrating the opening of its Haverhill office with a Ribbon Cutting Ceremony and Open House on Friday, August 9, from 12:00 – 1:30 pm at 145 South Main Street, Suite 1C, Haverhill, MA 01835. Among the distinguished guests will be, Achieve TMS East Psychiatrist, Dr. Renee Snow, Achieve TMS East’s Director of Marketing, Anita Taylor and members of the Merrimack Chamber of Commerce.

  • GlobeNewswire

    Groundbreaking Study Demonstrates Advantages of BrainsWay Deep TMS in Treating Major Depressive Disorder

    BrainsWay Ltd. (NASDAQ: BWAY, TASE: BWAY), a global leader in the advanced non-invasive treatment of brain disorders, today announced the publication of a third-party study which demonstrated that Deep Transcranial Magnetic Stimulation (dTMS) plus standard medication was significantly more effective at reducing depression levels among  Major Depressive Disorder (MDD) patients compared with standard medication alone. “This is an important study, because it provides the first head-to-head comparison of two different technologies that use transcranial magnetic stimulation (TMS) to treat depression,” said Markus Heilig, MD, PhD, a Professor of Psychiatry at Linköping University. The results appear in the July 2019 issue of the Journal of Psychiatric Research.

  • GlobeNewswire

    New Data Published in American Journal of Psychiatry Further Substantiates BrainsWay’s Deep TMS System for the Treatment of Patients with Obsessive Compulsive Disorder

    BrainsWay Ltd. (NASDAQ: BWAY, TASE: BWAY), a global leader in the advanced, non-invasive treatment of brain disorders, today announced new data from an article published in the last issue of the American Journal of Psychiatry demonstrating that its Deep TMS (dTMS) System showed a significant clinical benefit compared with placebo to treat Obsessive Compulsive Disorder (OCD) in a ~100-patient clinical trial (NCT02229903). OCD is a chronic and disabling disorder that affects ~1% of US adults. BrainsWay’s Deep TMS OCD treatment received De Novo clearance from the U.S. Food and Drug Administration (FDA) in August 2018 and is the only TMS platform that is FDA-cleared to treat OCD.

  • GlobeNewswire

    Chicago-based Psychiatrist, Dr. Fabian Carbonell, Debuts Innovative FDA-Cleared Treatment for Major Depressive Disorder (MDD) and Obsessive-Compulsive Disorder (OCD)

    Dr. Fabian Carbonell is the first psychiatrist in Chicago to offer patients with depression and obsessive-compulsive disorder the ability to be treated with BrainsWay’s Deep Transcranial Magnetic Stimulation (Deep TMS) therapy. Deep TMS administers magnetic waves through a cushioned helmet to targeted deep structures of the brain that have a large impact on patients’ symptoms.

  • GlobeNewswire

    BrainsWay Announces Shipment of 100th Deep Transcranial Magnetic Stimulation Helmet for the Treatment of Obsessive-Compulsive Disorder

    Since receiving De Novo clearance from FDA in August 2018, the Company has shipped OCD coils to 100 sites across the U.S. JERUSALEM and HACKENSACK, N.J., June 24, 2019 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE:BWAY) (BrainsWay” or the “Company”), a commercial stage medical device company focused on the development and sale of non-invasive neuromodulation products using the Company’s proprietary Deep Transcranial Magnetic Stimulation system (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD), today announced the shipment of the 100th Deep TMS helmet for the treatment of OCD in adults since receiving De Novo clearance from the U.S. Food and Drug Administration for this indication in August 2018.